{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:34:18Z","timestamp":1781649258462,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening manifestation of antiphospholipid syndrome (APS), which is frequently later diagnosed with high mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 54-year-old woman with a history of livedo reticularis presented with fever for four days, hematuria for two days, and impaired consciousness and petechiae for one day. Laboratory tests indicated thrombocytopenia, anemia, elevated indirect bilirubin and lactate dehydrogenase levels, as well as elevated free hemoglobin, isolated C3d positivity on direct antiglobulin test, and positive lupus anticoagulant and anti-cardiolipin IgG (aCL-IgG). A diagnosis of autoimmune hemolytic anemia and thrombocytopenia was established, and high-dose methylprednisolone combined with intravenous immunoglobulin therapy was initiated. On day 4, a tricuspid valve thrombus was detected and argatroban was initiated. Although the isolated LA positivity and low-titer aCL-IgG did not fulfill classic APS criteria, the definitive thrombosis led us to strongly suspect quasi-seronegative APS, prompting an increased methylprednisolone dose. On day 6, the platelet count dropped again, and a diagnosis of CAPS was suspected, prompting the administration of methylprednisolone pulse therapy along with plasma exchange. On day 6, the platelet count dropped again, and the patient received methylprednisolone pulse along with plasma exchange treatment. On day 10, leukopenia complicated mixed bacterial infections were developed. On day 11, subarachnoid hemorrhage occurred, leading to discontinuation of anticoagulant. Ultimately, the patient died with the worsened infections. Autopsy revealed extensive thrombosis and severe disseminated mixed infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early manifestations of CAPS may be atypical, so early identification is crucial for treatment. Following steroid pulse therapy, vigilance for fungal infections is essential, with empirical antifungal therapy initiated when necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1764711","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:39:48Z","timestamp":1777527588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Catastrophic antiphospholipid syndrome complicated with multiple infections: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingli","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Emergency, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Liang","sequence":"additional","affiliation":[{"name":"Emergency Department, Zhengzhou Central Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Emergency, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Emergency, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460317","article-title":"Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome","volume":"15","author":"Carrara","year":"2024","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241272678","article-title":"Dramatic devastative complications in a patient with catastrophic antiphospholipid syndrome: a case report and literature review","volume":"12","author":"Shakhshir","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don't know about catastrophic antiphospholipid syndrome","volume":"63","author":"Rodr\u00edguez-Pint\u00f3","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030733","article-title":"Antiphospholipid syndrome: a comprehensive clinical review","volume":"14","author":"Patriarcheas","year":"2025","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18745","article-title":"A diagnostic dilemma: catastrophic or seronegative antiphospholipid syndrome","volume":"13","author":"Enescu","year":"2021","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70785","article-title":"Seronegative catastrophic antiphospholipid syndrome: A case report of a deadly diagnosis","volume":"16","author":"Qadir","year":"2024","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak","year":"2020","journal-title":"Crit Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010668","article-title":"Catastrophic antiphospholipid syndrome","volume":"25","author":"Bitsadze","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2024_91-602","article-title":"Intravenous unfractionated heparin vs. Therapeutic plasma exchange in patients with autoimmune disease with acute thrombotic events: sampling in a case of catastrophic antiphospholipid syndrome","volume":"91","author":"Lin","year":"2024","journal-title":"J Nippon Med School"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38851","article-title":"Catastrophic antiphospholipid syndrome and renal failure: an unexpected recovery after three years on dialysis","volume":"15","author":"Alferes","year":"2023","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42012","article-title":"Catastrophic antiphospholipid syndrome: a rare cause of acute heart failure","volume":"15","author":"Elmusa","year":"2023","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320951260","article-title":"16th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/19714009241247469","article-title":"Vessel wall imaging in the diagnosis of antiphospholipid syndrome presenting as Moyamoya syndrome-A case report","volume":"38","author":"Yang","year":"2025","journal-title":"Neuroradiol J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0481-0","article-title":"The challenge of bleeding in antiphospholipid antibody-positive patients","volume":"17","author":"Pazzola","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17783","article-title":"Early use of eculizumab for catastrophic antiphospholipid syndrome","volume":"196","author":"Ribes","year":"2021","journal-title":"Brit J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \"CAPS Registry","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:39:49Z","timestamp":1777527589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1764711"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1764711","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1764711"}}